Efficacy and Safety of Metformin and Atorvastatin Combination Therapy vs. Monotherapy with Either Drug in Type 2 Diabetes Mellitus and Dyslipidemia Patients (ATOMIC): Double-Blinded Randomized Controlled Trial.
Jie-Eun LeeSeung Hee YuSung Rae KimKyu Jeung AhnKee-Ho SongIn-Kyu LeeHo-Sang ShonIn Joo KimSoo LimDoo-Man KimChoon Hee ChungWon-Young LeeSoon Hee LeeDong Joon KimSung-Rae ChoChang Hee JungHyun Jeong JeonSeung-Hwan LeeKeun-Young ParkSang Youl RheeSin Gon KimSeok O ParkDae Jung KimByung Joon KimSang Ah LeeYong-Hyun KimKyung-Soo KimJi A SeoIl Seong Nam-GoongChang Won LeeDuk Kyu KimSang Wook KimChung Gu ChoJung Han KimYeo-Joo KimJae-Myung YooKyung Wan MinMoon-Kyu LeePublished in: Diabetes & metabolism journal (2024)
The addition of atorvastatin to metformin improved HbA1c and LDL-C levels to a significant extent compared to metformin or atorvastatin alone in diabetes and dyslipidemia patients. This study also suggested metformin's preventive effect on the glucose-elevating potential of atorvastatin in patients with type 2 diabetes mellitus and dyslipidemia, insufficiently controlled with exercise and diet. Metformin and atorvastatin combination might be an effective treatment in reducing the CVD risk in patients with both diabetes and dyslipidemia because of its lowering effect on LDL-C and glucose.
Keyphrases
- combination therapy
- randomized controlled trial
- end stage renal disease
- type diabetes
- ejection fraction
- newly diagnosed
- cardiovascular disease
- peritoneal dialysis
- prognostic factors
- systematic review
- emergency department
- risk assessment
- adipose tissue
- blood pressure
- blood glucose
- open label
- skeletal muscle
- weight loss
- climate change